Operator
Welcome to the DBV Technologies Update Conference Call. [Operator Instructions] Please note this event is being recorded.
I would now like to turn the conference over to Jonathan Neely. Please go ahead, sir.
Jonathan Neely
Thank you, operator. This afternoon, DBV Technologies issued a press release announcing positive top line results from its Phase III VITESSE clinical trial of the VIASKIN Peanut patch in children aged 4 to 7 years old. This press release is available in the Press Releases section of the DBV Technologies website.
Before we begin, please note that today’s call may include a number of forward-looking statements, including, but not limited to, comments regarding the therapeutic potential of VIASKIN Peanut and EPIT, our clinical and regulatory development plans, the design of our anticipated clinical trials, the timing and results of interactions with regulatory agencies, plans and expectations with respect to the submission of BLAs to FDA, expectations around the BLA’s potential eligibility for priority review, anticipated support for the BLA submission, the exercise by investors of certain warrants issued as part of the financing announced on March 27, 2025, and the anticipated use of proceeds. Our forecast of our cash runway and the ability of any of our product candidates, if approved, to improve the lives of patients with food allergies.
These forward-looking statements are
